BCM
TVRD

Burrage Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Burrage Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$3.91M – 28
2021
Q1 		$3.91M Buy
+5,000
New +$3.42M 3.17% 14
2020
Q2 		– Sell
-7,188
Closed -$3.29M – 31
2020
Q1 		$3.29M Sell
7,188
-706
-9% -$384K 3.24% 14
2019
Q4 		$4.58M Buy
+7,894
New +$5.54M 3.07% 13

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Burrage Capital Management's TVRD Position: Q2 2021 in Review

Burrage Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 5,000 shares — an estimated $3.91M sold.

Burrage Capital Management first reported a position in TVRD in Q4 2019 and held it in 3 quarters. The position peaked at $4.58M in Q4 2019. 172 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Burrage Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Burrage Capital Management sold 5,000 Tvardi Therapeutics shares in Q2 2021, an estimated $3.91M.
  • Burrage Capital Management first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 3 quarters.
  • Burrage Capital Management's Tvardi Therapeutics position peaked at $4.58M in Q4 2019.
  • 172 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.